Endocryte Ipo Analysis

ENDOCRYTE IPO ANALYSIS The family that I chose to conduct my IPO on is called Endocyte. Endocyte just went public in July 2011 and is currently being traded on the NASDAQ with a Global Market symbol of (ECYT). Here is a little background on Endocyte as a participation as well as the industry they are in: Endocyte is a biopharmaceutical company developing butted therapies for the treatment of cancer and rabble-rousing illnesss. The company uses proprietary technology to create novel small molecule drug conjugates, or SMDCs, and comrade imaging diagnostics. SMDCs combat-readyly target receptors that are over-expressed on pathologic cells, relative to rosy-cheeked cells. This targeted cost is knowing to enable the treatment of diligents with highly active drugs at greater doses, delivered more oft, and over longer periods of time than would be possible with the untargeted drug alone. Endocyte is also developing companion imaging diagnostics for each of the SMDCs tha t are designed to site the patients whose disease over-expresses the target of the therapy and who are therefore more apparent to service from treatment.

This combination of an SMDC with its companion imaging diagnostic is designed to personalize the treatment of patients by delivering effective therapy, selectively to diseased cells, in the patients most likely to benefit. The bakshis SMDC, EC145, targets the pteroylglutamic acid receptor, which is frequently over-expressed in some of the most prevalent, and difficult to treat self-coloured tumour interpretations, including ovarian, non-small cell lung, breast, colorectal, kidney, endometrial and other cancers. They identif! y the front of the folate receptor in cancer patients by development EC20, a proprietary companion imaging diagnostic for EC145. Endocyte has elect platinum-resistant ovarian cancer, or PROC, a highly treatment-resistant disease, as its lead indication for development of EC145 because of the high unmet need in treating this patient tribe and the high percentage...If you want to get a proficient essay, line of battle it on our website: BestEssayCheap.com

If you want to get a full essay, visit our page: cheap essay